Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

ANAVEX 2-73 advances Phase I clinical trial for Alzheimer's disease
Sources News Release

http://www.sources.com/Releases/NR1292.htm

Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written:  26/05/2011
Year Published:  2011  
Resource Type:  Article

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs

Abstract:  Hoboken, NJ – May 23, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the first group of healthy human volunteers in the initial dose step, the Safety Review Committee for ANAVEX 2-73 unanimously approved skipping the 5 mg dose and moving directly to the 10 mg dose step. The next group of eight he...
To read the full release go to http://www.sources.com/Releases/NR1292.htm

Topics


Sources-journalists use the sources website to find you


AlterLinks
c/o Sources


© 2018. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.